Response to Dabrafenib and Trametinib of a Patient with Metaplastic Breast Carcinoma Harboring a BRAF V600E Mutation

BACKGROUND: Metaplastic breast carcinomas are rare and carry poor prognoses. They are also more aggressive than other breast cancers and are known for their resistance to chemotherapy. Prolonged treatment with dabrafenib and trametinib is a therapy for malignant melanoma that improves the progressio...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Case Rep Oncol Med
Main Authors: Seo, Takuji, Noguchi, Emi, Yoshida, Masayuki, Mori, Taisuke, Tanioka, Maki, Sudo, Kazuki, Shimomura, Akihiko, Yonemori, Kan, Fujiwara, Yasuhiro, Tamura, Kenji
Formato: Artigo
Idioma:Inglês
Publicado em: Hindawi 2020
Assuntos:
Case Report
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7079252/
https://ncbi.nlm.nih.gov/pubmed/32206360
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1155/2020/2518383
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados